Dali Li
dlli@bio.ecnu.edu.cn
English, Chinese
Shanghai
East China Normal University
Life Sciences
  • 2007 - PhD in Genetics, Hunan Normal University
  • Joint research at Texas A&M University during PhD
  • Recipient of the 'Outstanding Youth Fund'
  • 2009-2014 - East China Normal University, Promoted from Associate Professor to Researcher
  • Current - Director at Shanghai Frontiers Science Research Base for Gene Editing and Cell Therapy
  • Current - Deputy Director at Shanghai Key Laboratory of Regulatory Biology
  • Current - Director at Minhang Experimental Animal Center, East China Normal University
  • 2018 - First Prize in Natural Science Award from the Ministry of Education (Ranked second)
  • 2018 - Second Prize in Science and Technology Progress Award from Hainan Province (Ranked fourth)
Genetic diseases: Clinical challenges, lack of effective treatments for most known genetic diseases, high impact on families and society, especially children.
Gene therapy: Development and application challenges, potential in treating genetic diseases, recent market introductions of gene therapy products.
  • Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL, Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, Zhang L, Wei G, Tian Y, Zhao K, Chen A, Tan B, Cui J, Li D, Li Y, Qi Y, Wang D, Wu Y, Li D, Du B, Liu M, Huang H, 2022
  • CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric β0/β0 transfusion-dependent β-thalassemia, Fu B, Liao J, Chen S, Li W, Wang Q, Hu J, Yang F, Hsiao S, Jiang Y, Wang L, Chen F, Zhang Y, Wang X, Li D, Liu M, Wu Y, 2022
Genetic Diseases Clinical Challenges Treatment Scarcity Societal Impact Children Gene Therapy Development Challenges Application Challenges Market Introduction Therapeutic Potential

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.